Posts

Posted on

Greenbacker Renewable Energy Company LLC Acquires Solar Portfolio Totaling 80 MW

New York, NY, Nov. 16, 2020 (GLOBE NEWSWIRE) — Greenbacker Renewable Energy Company LLC (“GREC”) announced today that, through a wholly-owned subsidiary, it purchased a to-be-constructed 80 MW solar project from Broad Reach Power LLC. The project, Fall River Solar, is located in Fall River County, South Dakota and has a 20-year Power Purchase Agreement (“PPA”) in place with the investment-grade utility Black Hills Power, Inc. (“BHP”). Greenbacker will oversee the construction which is expected to reach COD in Q4 2022.

“We’re excited to have worked with Broad Reach Power on our largest solar project to date.” said Charles Wheeler, CEO of Greenbacker. “Expanding our solar portfolio in South Dakota will provide a clean energy option and a source for local employment in the state. We see tremendous potential in large scale pipeline investments such as Fall River Solar for both the people of South Dakota and our shareholders.”

“We also enjoyed our collaboration with the Greenbacker team and look forward to seeing this project continue to advance,” added Broad Reach Power Managing Partner and Chief Executive Officer Steve Vavrik.

With the acquisition of Fall River Solar, Greenbacker will own approximately 753.5 MW of generating capacity (including assets that are to be constructed), comprising 529.8MW of utility-scale and distributed solar facilities, 192.6MW of wind facilities, 19.1 MW of battery storage, and 12.0MW of biomass facilities.


About Greenbacker Renewable Energy Company

Greenbacker Renewable Energy Company LLC is a publicly reporting, non-traded limited liability energy company that acquires and manages income-generating renewable energy and energy efficiency projects, and other energy-related businesses. The projects in which we invest, such as solar and wind facilities, sell power under long-term contract to high credit worthy counterparties such as utilities, municipalities, and corporations. For more information, please visit www.greenbackercapital.com.


About Broad Reach Power

Broad Reach Power is a utility-scale storage independent power producer (IPP) based in Houston backed by leading energy investors EnCap Investments L.P., Yorktown Partners, and Mercuria Energy. The company owns a five gigawatt portfolio of utility scale solar and energy storage power projects in Montana, California, Wyoming, Utah and Texas which give utilities, generators and customers access to technological insight and tools for managing merchant power risk so they can better match supply and demand. Broad Reach is led by a team comprised of solar, wind, and storage experts who have delivered more than four gigawatts of projects and have a combined 80 years of experience in the field. For more information about the company, visit www.broadreachpower.com. 


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results to differ materially from those anticipated at the time the forward-looking statements are made. Although Greenbacker believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. Greenbacker undertakes no obligation to update any forward-looking statement contained herein to conform to actual results or changes in its expectations.

Media Contacts:

Greenbacker:

Joseph Kuo / Chris Clemens
Haven Tower Group
424 317 4851 or 424 317 4854
[email protected]		 Broad Reach Power

Mike Gehrig
Pierpont Communications
512 448-4950
[email protected]



Posted on

Cerevance’s CVN058 Achieves Primary Endpoint in Phase Ib Schizophrenia Cognition Study

Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).

“A single dose of CVN058 elicited a statistically significant improvement in mismatch negativity (MMN), an auditory evoked potential generated in the cerebral cortex that is typically impaired in schizophrenics,” noted David H. Margolin, M.D., Ph.D., senior vice president of clinical and translational medicine at Cerevance. “The normalization of MMN brainwaves, a biomarker of cortical dysfunction, leads us to believe our approach can potentially improve diverse aspects of cognition in schizophrenic patients.”

CVN058 is a novel, brain-penetrant, small-molecule antagonist of the type 3 receptor for serotonin, an important neurotransmitter. The Phase 1b, double-blind, placebo-controlled, three-period cross-over study evaluated CVN058 target engagement in the cerebral cortex by measuring mismatch negativity (MMN) as a pharmacodynamic marker.

Nineteen male and female subjects with schizophrenia or schizoaffective disorder, aged 18 to 50 years old, received a single oral dose of CVN058 (low-dose, 15 mg or 75 mg; high-dose, 150 mg) or matching placebo at each study visit. MMN and other cortical biomarkers were recorded in the hours after dosing. The sequence in which a subject took each of the three regimens was randomized, with a minimum of a seven-day washout between doses. These treatments had no serious or severe adverse effects.

The number of diagnosed prevalent cases of schizophrenia with comorbid cognitive impairment is expected to exceed 4 million in the seven major pharmaceutical markets in 2022. Cognitive impairment associated with schizophrenia (CIAS)—which may include deficits in attention, working memory and executive function—has a negative impact on patients’ quality of life and ability to function. Although cognitive symptoms in schizophrenia are well characterized, no formal diagnostic criteria exist. Furthermore, no pharmacological agents are approved to treat the condition, and no marketed therapy tested to date has established clear, meaningful efficacy, which underscores the difficulty of drug development in this arena and accentuates the need for proven treatment options.

“The cognitive impairment experienced by many patients with schizophrenia desperately needs an effective treatment,” said Daniel C. Javitt, M.D., Ph.D., lead investigator and a world-renowned researcher in the study of schizophrenia and cognition. Dr. Javitt directs the Schizophrenia Research Program at the Nathan S. Kline Institute for Psychiatric Research and is also Professor and Director of the Division of Experimental Therapeutics in the Department of Psychiatry and Neuroscience at Columbia University College of Physicians and Surgeons. “We are very encouraged by CVN058’s results in our MMN translational study and look forward to confirming its potential cognitive benefits in future clinical trials.”

About Cerevance

Cerevance, a private, clinical-stage pharmaceutical company focused on brain diseases, is applying a new technology, called NETSseq, to reveal transcriptional and epigenetic differences between specific cell types in mature human brains. NETSseq profiles neuronal and glial cell populations at depths not possible with other approaches, generating unprecedented data sets and insights. The company has thus far partnered with 17 brain banks around the world to assemble a growing collection of more than 8,000 clinically annotated, human brain tissue samples from healthy and diseased donors spanning nine decades in age. By applying NETSseq to specific cell types critical to circuits disrupted by disease and comparing vulnerable and resilient cell populations, Cerevance’s scientists have begun identifying targets and advancing a pipeline of novel therapeutics that modulate them for CNS diseases.

Contacts

Cerevance:

Robert Middlebrook, +1-408-220-5722

Media:

Andrew Mielach, [email protected], +1-646-876-5868



Posted on

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Wells Fargo & Company – WFC

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Wells Fargo & Company – WFC

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Wells Fargo & Company (NYSE: WFC) between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Wells Fargo investors under the federal securities laws.

To join the Wells Fargo class action, go to http://www.rosenlegal.com/cases-register-1985.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loan customers were of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, collateralized loan obligations (“CLOs”) and commercial mortgage backed securities (“CMBS”) on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, Wells Fargo’s Class Period statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading and (8) as a result of the foregoing, Wells Fargo was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1985.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Posted on

RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib – Data Expected in the Coming Weeks

Enrollment completed in the U.S. Phase 2 study evaluating opaganib’s safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia

A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled – on track to enroll all 270 patients and report topline data in Q1/2021

Potential emergency use applications expected as early as Q1/2021

Opaganib’s unique dual anti-inflammatory and antiviral activity acts on the cause and effect of COVID-19 disease with host cell targeting, minimizing potential for resistance due to viral mutations

PR Newswire

TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has completed enrollment of the last patient in the study. The study is not powered for statistical significance. Topline data is expected in the coming weeks.

 

RedHill Biopharma Logo

 

“Completing enrollment in this U.S. Phase 2 study of orally administered opaganib in severe COVID-19 is a key milestone, indicating that we are just weeks away from important safety data and increased understanding of the potential of opaganib. In parallel, our global Phase 2/3 study is approximately 50% enrolled and is expected to undergo its first pre-planned safety analysis in the coming days and report topline data in the first quarter of 2021. We are compiling a robust data set to support the planned emergency use applications, expected as early as next quarter, subject to study success.” said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill. “Opaganib has a demonstrated unique dual mode of action that is both anti-inflammatory and antiviral – acting on the cause and the effect of COVID-19. Moreover, opaganib acts on a host cell component involved in viral replication and not the virus itself, which could minimize issues of resistance due to emergence of viral mutations. In light of the encouraging data from patients with severe COVID-19 treated with opaganib under compassionate use[2] and the potent anti-SARS-CoV-2 activity that opaganib has demonstrated in vitro, we are excited to see the data from the U.S. Phase 2 study and look to rapidly complete the global Phase 2/3 development program for opaganib toward potential emergency use authorization applications.”

The randomized, double-blind, placebo-controlled Phase 2 study with opaganib (NCT04414618) enrolled 40 patients in clinical sites across the U.S. The study is not powered for statistical significance and is focused on safety evaluation and identifying a signal of efficacy. Patients in the study were randomized at a 1:1 ratio to receive either opaganib or placebo on top of standard-of-care. The primary objective of the study is to evaluate the reduction in total oxygen requirement over the course of treatment for up to 14 days. Secondary endpoints include time to 50% reduction in oxygen requirements, the proportion of patients without fever at Day 14, and proportion with negative nasal swabs at Day 14.

In parallel, the global Phase 2/3 study with opaganib in patients with severe COVID-19 pneumonia (NCT04467840) is approximately 50% enrolled and is expected to report topline data in the first quarter of 2021. The study is being conducted across 21 clinical sites and is on track to enroll up to 270 patients. A first unblinded review of safety data from the first 70 patients enrolled in the study by an independent Data and Safety Monitoring Board (DSMB) is expected in the coming days. An unblinded futility interim analysis will be conducted by the DSMB in the coming weeks, evaluating data from the first 135 subjects that have reached the primary endpoint. This study is focused on, and powered for, efficacy evaluation. The study has been approved in the UK, Italy, Russia, Mexico, Brazil and Israel, with further expansion ongoing. 

The clinical studies with opaganib are intended to support potential emergency use applications as early as the first quarter of 2021, subject to positive results. 

About Opaganib (ABC294640, Yeliva®)

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component of viral replication, potentially minimizing the likelihood of viral resistance. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer. Opaganib is also being evaluated in a global Phase 2/3 study and a U.S. Phase 2 study for the treatment of COVID-19.

Preclinical data have demonstrated both anti-inflammatory and antiviral activities of opaganib, with the potential to reduce inflammatory lung disorders, such as pneumonia, and mitigate pulmonary fibrotic damage. Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies[3] have demonstrated that opaganib decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids.

Opaganib was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful preclinical studies in oncology, inflammation, GI, and radioprotection models, as well as a Phase 1 clinical study in cancer patients with advanced solid tumors and an additional Phase 1 study in multiple myeloma.

Under a compassionate use program, COVID-19 patients (as classified by the WHO ordinal scale) were treated with opaganib in a leading hospital in Israel. Data from the treatment of these first patients with severe COVID-19 with opaganib have been published[2]. Analysis of treatment outcomes suggested substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a retrospective matched case-control group from the same hospital. All patients in the opaganib-treated group were discharged from hospital on room air without requiring intubation and mechanical ventilation, whereas 33% of the matched case-control group required intubation and mechanical ventilation. Median time to weaning from high-flow nasal cannula was reduced to 10 days in the opaganib-treated group, as compared to 15 days in the matched case-control group. 

The development of opaganib has been supported by grants and contracts from U.S. federal and state government agencies awarded to Apogee Biotechnology Corp., including from the NCI, BARDA, the U.S. Department of Defense and the FDA Office of Orphan Products Development.

The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.   

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults with non-cancer pain[4], Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[5], and Aemcolo® for the treatment of travelers’ diarrhea in adults[6]. RedHill’s key clinical late-stage investigational development programs include: (i) RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva®), a first–in–class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi) RHB–106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words and includes statements regarding the timing of the reporting of data from the U.S. Phase 2 trial evaluating opaganib, the timing of potential emergency use applications of opaganib. Reporting of topline data, safety analysis and of unblinded futility interim analysis for the global Phase 2/3 study with opaganib. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk that the Company’s Phase 2/3 study evaluating opaganib will not be successful; the risk of a delay in receiving data to support emergency use applications or in making such emergency use applications, if at all; the risk that the U.S. Phase 2 clinical study evaluating opaganib will not be successful and the risk that the reporting of data from this clinical study will be delayed if at all; the risk that the Company will not initiate the Phase 2/3 study for opaganib in certain geographies, will not expand this study to additional countries and that it will not be successful and that enrollment, reporting of topline data, safety analysis and/or unblinded futility interim analysis will be delayed; the risk that other COVID-19 patients treated with opaganib will not show any clinical improvement; the development risks of early-stage discovery efforts for a disease that is still little understood, including difficulty in assessing the efficacy of opaganib for the treatment of COVID-19, if at all; intense competition from other companies developing potential treatments and vaccines for COVID-19; the effect of a potential occurrence of patients suffering serious adverse events using opaganib under compassionate use programs, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

References:

[1] Opaganib is an investigational new drug, not available for commercial distribution.

[2] Kurd R, Ben-Chetrit E, Karameh H, Bar-Meir M, Compassionate Use of Opaganib For Patients with Severe COVID-19. medRxiv 2020.06.20.20099010; doi: https://doi.org/10.1101/2020.06.20.20099010

[3] Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.

[4] Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.  

[5] Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[6] Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

 


Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

+972-54-6543-112


[email protected]

 


Media contact (U.S.):

Bryan Gibbs

Vice President

Finn Partners

+1 212 529 2236


[email protected]

 

 

Cision View original content:http://www.prnewswire.com/news-releases/redhill-biopharma-completes-enrollment-for-covid-19-us-phase-2-study-with-opaganib–data-expected-in-the-coming-weeks-301173725.html

SOURCE RedHill Biopharma Ltd.

Posted on

Utility Mobile Apps Provider Backuptrans Sees Significant Revenue Uplift Since Switching to 2Checkout

An optimized cart, out-of-the-box merchandizing tools, more flexibility and support, as well as affiliate sales have contributed to this improvement

ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) — 2Checkout (now Verifone), the leading all-in-one monetization platform for global businesses, today announced that Backuptrans – a leading developer in mobile backup-and-restore utility software – has doubled its online revenue since switching to 2Checkout’s Avangate monetization platform. The increase is attributed to an optimized shopping cart with 13% better cart conversion, easy-to-use promotional and cross-selling functionality, more localization options, and a 35% surge in sales generated by the Avangate Affiliates Network.

Prior to moving to 2Checkout’s monetization platform, Backuptrans had made slow progress on improving its eCommerce operations and was behind in terms of being able to service its customers in a modern and seamless way. Backuptrans was connected to 2Checkout’s Avangate affiliate network, generating around 20% of online sales from this channel. The switch to the full 2Checkout monetization platform was seamless, and the software company immediately noticed improved results across the board.

Backuptrans now benefits from 2Checkout’s all-in-one Avangate monetization platform, including advanced eCommerce, global payments, and subscription billing capabilities. Backuptrans opted for the reseller model, in which 2Checkout relieves the merchant, at a global level, of the burden related to sales tax management, invoicing, and compliance. In addition, the 2Checkout team has helped Backuptrans accelerate communication and promotional activities with the affiliate community, showing notable results from this channel: a 35% increase in sales generated from affiliates.

“We have doubled our online revenue since switching to 2Checkout’s eCommerce engine, by getting a better cart conversion rate to start with. We love the support we get from the 2Checkout team and the fact that they did not stop at the cart improvement. We are employing marketing and merchandizing tools to continue boosting our sales – both direct and via affiliates – and overall eCommerce operations, ultimately providing a better customer experience,” mentioned Eric NG, CEO at Backuptrans.

“We are very pleased with the progress Backuptrans has made around eCommerce and the increase in revenue they obtained since switching to 2Checkout. Especially when selling internationally, the complexity of digital commerce increases, and we are here to simplify operations for our clients so they can stay focused improving the products and services of their end-customers. With our local support for China as well as at a global level, we set our clients up for success and help them accelerate revenue without barriers. Their growth is our priority,” said Maggie Lee, Business Development, APAC, for 2Checkout.

For more information on other client success stories, view the dedicated page on the 2Checkout website.

About Backuptrans

Backuptrans is a leading software developer in cutting-edge mobile management field. Their software ranges from iPhone SMS backup and restore, Android SMS backup and restore, iPhone SMS to Android transfer, Android SMS to iPhone transfer, iPhone Contacts backup and restore, Android Contacts backup and restore, iPhone Contacts to Android transfer, Android Contacts to iPhone transfer and iTunes Backup Extractor etc.

More information on https://www.backuptrans.com/  

Ab
out 2Checkout
(now Verifone)

2Checkout (now Verifone) is the leading all-in-one monetization platform for global businesses built to help clients drive sales growth across channels and increase market share by simplifying the complexities of modern commerce. 2Checkout’s digital services, including global payments, subscription billing, merchandising, taxes, compliance and risk, help clients stay focused on innovating their products while delivering exceptional customer experiences.

In August 2020, leading global payments solution provider Verifone acquired 2Checkout, further solidifying its commitment to providing seamless and frictionless experiences to customers globally through innovative and next-generation hardware and cloud services. 2Checkout will become Verifone, and the unified company will enable omnichannel commerce wherever and whenever clients’ shop.

Get more information at www.2checkout.com.



Media Contact:
Delia Ene, 2Checkout
Email: [email protected] 
Tel: +31 20 890 8080 ext.: 4654

Posted on

Death of R. Bruce Duncan, Canada Coal Inc.’s Chief Executive Officer

MISSISSAUGA, Ontario, Nov. 16, 2020 (GLOBE NEWSWIRE) — Canada Coal Inc. (the “Company”) (NEX: CCK):

It is with profound sadness that the management and Board of Directors of the Company shares the news that its Chief Executive Officer, R. Bruce Duncan, passed away suddenly on Thursday, November 12, 2020.

The Board of the Company states that “we are deeply shocked and saddened by Bruce’s passing and our thoughts and deepest condolences are extended to Bruce’s family and friends.”

With this development, the Board has appointed the Company’s Chief Financial Officer, Olga Nikitovic, C.P.A., C.A., as its interim Chief Executive Officer, effective immediately.

On behalf of the Board of Directors

Olga Nikitovic
Interim Chief Executive Officer
Phone: 905-813-8952
Website: www.canadacoal.com
E-mail: [email protected]



Posted on

Aurora Cannabis Closes Previously Announced Upsized Underwritten Public Offering Over-Allotment Option Exercised in Full

PR Newswire

NYSE | TSX: ACB

EDMONTON, AB, Nov. 16, 2020 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced overnight marketed public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$172,500,000. The Company sold 23,000,000 Units at a price of US$7.50 per Unit, including 3,000,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one

common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 40 months following the closing date of the Offering at an exercise price of US$9.00 per Warrant Share, subject to adjustment in certain events.

BMO Capital Markets and ATB Capital Markets acted as the bookrunners for the Offering.

The Company plans to use the net proceeds of the Offering to fund growth opportunities, working capital, and other general corporate purposes.

In connection with the Offering, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 28, 2020 (the “Base Shelf Prospectus”) with the securities commissions or similar securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (the “SEC”) as part of the Company’s registration statement on Form F-10 (the “Registration Statement”) under the U.S./Canada Multijurisdictional Disclosure System. The Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement contain important detailed information about the Company and the Offering.

Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR at www.sedar.com and copies of the Prospectus Supplement and the Registration Statement are available on EDGAR at www.sec.gov. Copies of the Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from BMO Capital Markets by contacting BMO Capital Markets, Brampton Distribution Centre C/O The Data Group of Companies, 9195 Torbram Road, Brampton, Ontario, L6S 6H2 or by telephone at (905) 791-3151 Ext 431 or by email at [email protected] or from BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036 (Attn: Equity Syndicate), or by telephone at (800) 414-3627 or by email at [email protected]. Copies of such documents may also be obtained from ATB Capital Markets Inc., Attn: Gail O’Connor, 410-585 8th Ave SW, Calgary, Alberta, T2P 1G1, (403) 539-8629 or by email from [email protected].

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aurora 

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at www.auroramj.com.

Aurora’s common shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements“). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include statements regarding the expected use of proceeds of the Offering. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 24, 2020 (the “AIF“) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.edgar.gov, any of which could cause the Company to change its use of proceeds from the Offering. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-closes-previously-announced-upsized-underwritten-public-offering-over-allotment-option-exercised-in-full-301173714.html

SOURCE Aurora Cannabis Inc.

Posted on

Morguard North American Residential REIT Declares November 2020 Distribution of $0.0583 per Unit

Canada NewsWire

MISSISSAUGA, ON, Nov. 16, 2020 /CNW/ – Morguard North American Residential Real Estate Investment Trust (the “REIT”) (TSX: MRG.UN) today announced that it has declared a distribution of $0.0583 per unit for the month of November 2020.  The distribution will be payable on December 15, 2020 to unitholders of record as at November 30, 2020.

About Morguard North American Residential REIT

The REIT is an unincorporated, open-ended real estate investment trust which owns, through a limited partnership, interests in Canadian residential apartment communities, located in Alberta and Ontario, and U.S. residential apartment communities located in Colorado, Texas, Louisiana, Illinois, Georgia, Florida, North Carolina, Virginia and Maryland.

For more information, please visit Morguard.com.

SOURCE Morguard North American Residential Real Estate Investment Trust

Posted on

Truist hires Karakaplan to lead newly formed Enterprise Payments Group

PR Newswire

CHARLOTTE, N.C., Nov. 16, 2020 /PRNewswire/ — Truist Financial Corporation (NYSE: TFC) today announced Sal Karakaplan has been hired as head of its newly formed Enterprise Payments Group.

Under Karakaplan’s leadership, the Enterprise Payments Group will be responsible for driving a coordinated strategy and execution across Truist’s payments businesses, enabling the delivery of next generation payment products, services, and infrastructure to meet clients’ needs and drive financial results.

“Payments is one of the most important and ubiquitous aspects of banking and will play an increasingly critical role in the future of banking,” said Mike Maguire, head of National Consumer Finance & Payments. “We are committed to making ongoing investments in payments, including the formation of this new group, to better position Truist to meet our clients’ needs and provide distinctive, secure, and successful client experiences.”

Karakaplan brings more than 20 years of payments experience including leadership roles in strategy, corporate development, and product management. Prior to joining Truist, Karakaplan spent five years at JPMorgan Chase in its payments strategy group where he worked across all payments domains. Prior to JPMorgan Chase, he spent 10 years at MasterCard in a number of roles spanning consulting, corporate strategy, M&A and product management.

“As the sixth largest bank in the country, Truist has a tremendous opportunity to build upon its newfound scale and bring innovative payment solutions to its clients,” said Karakaplan. “I’m thrilled to be joining the team and eager to help Truist succeed in its efforts to advance its positioning in the payments landscape.”

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspire and build better lives and communities. With 275 years of combined BB&T and SunTrust history, Truist has leading market share in many high-growth markets in the country. The company offers a wide range of services including retail, small business and commercial banking; asset management; capital markets; commercial real estate; corporate and institutional banking; insurance; mortgage; payments; specialized lending; and wealth management. Headquartered in Charlotte, North Carolina, Truist is the sixth-largest commercial bank in the U.S. with total assets of $499 billion as of September 30, 2020. Truist Bank, Member FDIC. Learn more at Truist.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/truist-hires-karakaplan-to-lead-newly-formed-enterprise-payments-group-301173690.html

SOURCE Truist Financial Corporation

Posted on

Scripps promotes finance leaders Perschke and Riegelsberger

PR Newswire

CINCINNATI, Nov. 16, 2020 /PRNewswire/ — The E.W. Scripps Company (NASDAQ: SSP) has promoted two of its finance leaders, effective immediately.


Dan Perschke
, 41, assistant controller, has been appointed vice president, controller. In this role, Perschke will be responsible for the company’s accounting systems, internal accounting controls, financial reporting and related accounting management. He joined Scripps in 2008 as a senior analyst of financial reporting. In 2015, he became the finance business partner for the Local Media division, and he became vice president, assistant controller in 2018. He began his career as an auditor with PwC.

Perschke earned a bachelor’s degree in accountancy and finance and a master’s degree in accountancy from Miami University. He is a certified public accountant and holds a certification as a Chartered Global Management Accountant and is a member of the American Institute of Certified Public Accountants and the Ohio Society of Certified Public Accountants.


Rebecca Riegelsberger
, 41, vice president of tax and treasury, has been appointed treasurer, vice president, tax, with responsibility for managing the company’s cash flow and debt, minimizing financial risk and overseeing all aspects of the tax function. She also will have oversight for financial investments, liquidity and capital growth and allocation. Riegelsberger has been with Scripps since 2015, serving as vice president of tax before her role was expanded in 2017 to also include treasury operations. From 2009 to 2015, she served as tax manager, then tax director for Scripps Networks Interactive. Riegelsberger began her career as a tax analyst at Duke Energy.

Riegelsberger earned a bachelor’s degree in accountancy and a master’s in business administration from the University of Cincinnati. She is a certified public accountant and a member of the American Institute of Certified Public Accountants and the Ohio Society of Certified Public Accountants.

Perschke and Riegelsberger will report to Lisa Knutson, executive vice president and chief financial officer, and to the new CFO when Knutson takes the role of leader of the new national networks business at the close of Scripps’ ION Media acquisition.

These promotions come after Scripps also appointed Doug Lyons, 63, senior vice president, controller and treasurer, to a new role as senior vice president, financial strategy and special projects. Lyons will report to Adam Symson, Scripps’ president and chief executive officer, and help the company navigate strategic opportunities tied to enterprise-level value creation.

During his more than 35 years at Scripps, Lyons has played a key role in every major transaction for the company. He joined Scripps in 1985 as assistant controller and later served as director of financial reporting and vice president of finance and administration. Lyons became vice president and controller in 2008, vice president, controller and treasurer in 2015, and senior vice president in 2017. Prior to joining Scripps, he was an audit manager for Deloitte.

Lyons earned a bachelor’s degree in accounting from University of Dayton. He is a certified public accountant and a member of the American Institute of Certified Public Accountants.

The promotions are a testament to the company’s focus on leadership development, said Adam Symson, president and CEO.

“Both Becky and Dan will bring invaluable expertise to their new senior leadership roles as they assume increased responsibilities for the company’s financial stewardship,” said Symson. “I am confident each will play critical roles as we continue on the path to become a larger and stronger Scripps.

“Doug has been a steady and trusted hand at the senior most level of this company for decades. His financial expertise, leadership and deep media experience have helped shape the Scripps story, and I look forward to working with him as we navigate the opportunity ahead.”


About Scripps


The E.W. Scripps Company (NASDAQ: SSP) is one of the nation’s leading media companies, focused on creating a better-informed world through a portfolio of news, information and entertainment brands. Scripps will become the nation’s largest television broadcaster, reaching 73% of U.S. television households through 108 stations in 76 markets, pending regulatory approval of its acquisition of ION Media. Committed to serving local audiences through objective journalism, Scripps operates 60 local TV stations in 42 markets. It is creating a national TV networks business that will include ION Media’s entertainment programming, Newsy’s straightforward headline and documentary news content and the five popular Katz broadcast networks including Bounce and Court TV. Scripps runs an award-winning investigative reporting newsroom in Washington, D.C., and is the longtime steward of the Scripps National Spelling Bee. Founded in 1878, Scripps has held for decades to the motto, “Give light and the people will find their own way.”

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/scripps-promotes-finance-leaders-perschke-and-riegelsberger-301173700.html

SOURCE The E.W. Scripps Company